Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/bjd/ljaf039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The UK-Irish Atopic eczema Systemic TherApy Register (A*STAR): baseline characteristics of the cohort.
Br J Dermatol
January 2025
Unit for Population-based and Paediatric Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, UK.
Methotrexate versus ciclosporin in the treatment of severe atopic eczema in children: an economic evaluation.
Br J Dermatol
January 2025
Unit for Paediatric and Population-based Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.
An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024.
Br J Dermatol
November 2024
Clinical Standards Unit, British Association of Dermatologists, Willan House, London W1T 5HQ, UK.
Article Synopsis
- Atopic dermatitis (AD) is a prevalent skin condition that can occur in individuals of any age, and while dupilumab shows promising efficacy as a monoclonal antibody therapy, its use has been linked to a higher occurrence of ocular side effects.
- The British Association of Dermatologists and the Royal College of Ophthalmologists developed guidance on how to manage these dupilumab-related ocular surface disorders (DROSD) after forming a multidisciplinary group to review literature and recommendations.
- Key recommendations include that treatment with dupilumab should not be delayed for most eye issues, hydration drops are not advised as preventive measures, and specific guidance is provided for managing DROSD in both children under 7 and those older, with a focus on
International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study.
J Eur Acad Dermatol Venereol
February 2025
Dermatology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
Background: Despite the widespread off-label use of methotrexate (MTX) for the treatment of atopic dermatitis (AD), there is limited high-quality evidence on dosing regimens and existing guidelines do not provide clear recommendations regarding dosing strategies.
Objective: The aim of this study was to achieve international consensus among AD experts to standardize the dosing regimen for MTX treatment in adults and children with AD.
Methods: An electronic Delphi (eDelphi) study was conducted from October 2021 to September 2022.
A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register.
Br J Dermatol
November 2024
Unit for Paediatric & Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, UK.
Article Synopsis
- The study compares the real-world effectiveness and safety of three treatments for atopic dermatitis: dupilumab, ciclosporin (CyA), and methotrexate (MTX), using data from the A-STAR register in the UK and Ireland.
- It involved 488 patients (adults and children) and measured treatment outcomes like the Eczema Area and Severity Index (EASI) and quality of life scales over 12 months.
- Results showed that dupilumab and CyA led to faster improvements in skin severity scores and overall patient outcomes compared to MTX, indicating dupilumab is an effective option in managing atopic dermatitis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!